Remi Therapeutics is pioneering breakthrough treatments that offer new hope to individuals with autism and their families. Through their innovative first-in-class therapies, the company is addressing critical unmet needs in autism care, targeting a community that has long been underserved by traditional pharmaceutical approaches.

Led by an experienced management team with deep expertise in neurodevelopmental disorders, Remi is developing therapeutic solutions that have the potential to meaningfully improve quality of life for those on the autism spectrum.

This comprehensive approach recognizes the complexity of autism and focuses on creating treatments that can make a real difference in the daily lives of patients and their caregivers, representing a significant step forward in autism therapeutics.

Despite autism affecting 1 in 31 children in the U.S. and imposing an estimated $1 trillion (by 2030) annual economic burden, there are no FDA-approved treatments specifically targeting the core symptoms of Autism. 

Right now, families dealing with autism face a major problem: there are no medicines made specifically for autism's main symptoms. This means doctors have to use medicines created for other conditions. Giving a child three or four different pills that were made for depression, ADHD, or sleep problems with the hope they might help with autism symptoms does not always address the symptoms. It's like trying to fix a computer with tools made for a car. 

This creates a huge opportunity for companies developing targeted autism therapies to capture a market where families are desperate for solutions that actually work. The challenge gets even bigger when you look at how different autism can be from person to person. 

Right now, the spectrum of symptoms lead many doctors to treat everyone the same way, but that's like giving everyone the same shoe size. It just doesn't fit most people. 

These problems make it hard for kids to do everyday things like go to school, make friends, or just be independent. Families spend huge amounts of money and time trying different medicines that often cause bad side effects like weight gain and feeling tired all the time, without really fixing what's wrong in the brain.

There is a clear gap in the market where targeted, symptom-specific treatments could transform millions of lives in a field crying out for change.

Remi Therapeutics is pioneering a new approach to treating autism through first-in-class therapies that target specific underlying pathologies rather than just managing symptoms. Our strategy leverages novel mechanisms of action with strong intellectual property protection, backed by extensive preclinical validation including improved cognition and addressing key pathologies identified by leading autism researchers like Dr. Jill James and Dr. Carl Nathan.

We have mitigated risk through a diversified portfolio of three independent assets targeting different patient subpopulations within the autism spectrum, with clear expansion opportunities beyond autism into broader markets.

This innovative platform approach is led by an experienced management team with over 30 years of pharmaceutical expertise, including CEO Brian Groch who has raised over $125 million and launched 30 products, supported by leadership with proven track records at major pharmaceutical companies like Pfizer, Merck, and Novartis, providing deep expertise in CNS drug development and commercialization.

RT0307 is being developed to help people with Autism by improving thinking, behavior, and social interaction which are core challenges for families today.

How It Works

It combines three powerful approaches in one therapy:

1. Boosting brain connections – helps people think and connect better with others.
2. Restoring balance in the brain – calms overactive signals that lead to hyperactivity.
3. Reducing brain inflammation – supports long-term brain health.

Why It’s Unique

• First of its kind to utilize a 3-in-1 approach specifically designed to target autism symptoms.
• Provides the benefits without the heavy sedation often caused by antipsychotics or polypharmaceutical approaches.
• Early clinical results demonstrate that this approach works well in validated autism models.

Learn More

RT8412 is being developed to boost focus and memory by targeting brain inflammation.

How It Works

1. Targets Core ADHD pathologies: cholinergic dysregulation, neuroinflammation and oxidative stress.
2. Non-Stimulant – no stimulant-related side effects.

Why It’s Unique

• Addresses massive unmet need - Targets attention and hyperactivity in 70% of autism patients who also have ADHD symptoms.
• Superior preclinical performance - Outperformed Ritalin (methylphenidate) in early studies.
• Non-stimulant alternative - Addresses core ADHD pathologies without stimulant-related side effects.
• Broad age applicability - Designed for both children and adults with attention, impulsivity, and hyperactivity symptoms.

Learn More

RT2234 is being developed to help people with Autism by improving thinking, behavior, and social interaction which are core challenges for families today.

How It Works

• Fights two brain problems at once - Targets both brain inflammation and cell damage, the main causes of Alzheimer's disease.
• Calms brain immune system - Uses a special pathway to reduce harmful brain inflammation without weakening the body's natural defenses.
• Protects brain cell energy - Helps brain cells produce more energy and activates the body's natural protection against cell damage.
• Improves memory function - Strengthens the brain areas responsible for learning and memory by boosting communication between brain cells.
• Maintains muscle-nerve connections - Keeps the signals between nerves and muscles working properly for better movement and strength.

Why It’s Unique

• Reduces inflammation safely - Lowers dangerous brain swelling and irritation while keeping the immune system strong and healthy
• Breakthrough technology - Uses an innovative "silent" approach that provides benefits without the tolerance problems that limit other drugs
• Gets into the brain effectively - Specially designed to cross the brain's protective barrier, solving a major challenge that stops many treatments from working
• Multiple benefits work together - Different healing pathways team up to create stronger results than treatments that only target one problem
• Potential Application to Alzheimer's Patients - Preclinical indications that it could deliver more effective treatment to Alzheimer's patients.

Learn More

RT2234 has the potential to attack Alzheimer's disease by fighting both brain inflammation and cell damage at the same time. The drug combines two medicines that work together - one calms down harmful brain swelling while the other protects brain cells from breaking down. Preclinical studies show it helps cognition and protects brain cells from the toxic proteins that cause Alzheimer's. Small human studies already show older adults can think faster after taking part of this treatment. This two-way approach could slow down or even stop Alzheimer's from getting worse, not just treat the symptoms.

Popular weight loss drugs like Ozempic help people lose weight, but they also cause dangerous muscle loss. RT2234 may solve this problem by protecting and building muscle while people use these weight loss treatments. The weight loss drug market will be worth $200 billion by 2031, and about $60 billion of that will need muscle protection treatments. If RT2234 captures just 15% of this new market, it could generate $9 billion in sales. This is a huge opportunity because millions of people are starting these weight loss drugs but need a way to keep their muscle strength and health.